Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy.
نویسندگان
چکیده
UNLABELLED We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy in patients with Parkinson disease dementia (PDD) to determine whether cognitive improvements would be reflected in changes of cerebral metabolic patterns, thus offering insight into the neural substrate of cognitive dysfunction in patients with PDD. METHODS We performed a serial PET study before (baseline) and after ChEI therapy on 10 patients with PDD, using statistical parametric mapping. Additionally, covariance analysis was performed to extract regions in which increased change in regional cerebral metabolism correlated significantly with increased Mini-Mental State Examination scores. RESULTS The statistical parametric mapping analysis indicated that significantly increased cerebral metabolism after ChEI therapy, compared with at baseline, was most evident in the left angular gyrus extending to the supramarginal area and left superior and middle frontal gyri. Additionally, cerebral metabolism was significantly increased in the right superior frontal and left middle orbitofrontal gyri. In contrast, the right fusiform gyrus showed significantly decreased metabolism after ChEI, compared with at baseline. In the correlation analysis, improvements in Mini-Mental State Examination scores after ChEI treatment were significantly associated with increased cerebral metabolism in the left supramarginal, orbitofrontal, and cingulate areas. CONCLUSION Our data suggest that prefrontal and parietal association areas may be relevant structures for the pharmacologic response to ChEI in patients with PDD.
منابع مشابه
Effects of rivastigmin tartarat in the therapy of patients with schizophrenia
Background Rivastigmin tartarat is a dual, reversible cholinesterase inhibitor (acetil and butril). Its chemical composition is (S)-N-ethyl-N-methyl-3-1-dimethylamin ethyl-phenyl carbamat hydrogen-(2R,3R)-tartrat. FDA has approved its use in treatment of Alzheimer dementia and dementia in combination with Parkison disease. In addition to this, results based on small clinical studies and case re...
متن کاملLongitudinal changes of cerebral glucose metabolism in semantic dementia.
BACKGROUND Semantic dementia (SD). OBJECTIVE To identify the pattern of decline of cerebral glucose metabolism in SD using cerebral (18)F-fluoro-2-desoxy-D-glucose positron emission tomography scanning ((18)F-FDG-PET). METHODS Eight patients with SD underwent (18)F-FDG-PET at baseline and at re-examination in average 15 months later. RESULTS Compared with healthy control subjects, patient...
متن کاملRegion-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective 18F-FDG-PET study.
OBJECTIVE The aim of this study was to examine the pattern of glucose uptake and the changes over time of metabolic deficits in patients with frontotemporal dementia (FTD). METHODS 10 patients who had received the clinical diagnosis of FTD underwent positron emission tomography scanning at the time of their first examination (baseline) and at follow-up (after 17.1 +/- 6.0 months). For statist...
متن کاملLongitudinal lipid profile variations and clinical change in Alzheimer's disease dementia
Hypercholesterolemia and statin use have been unevenly associated with clinical change in Alzheimer's disease dementia. In this longitudinal study, 192 consecutive outpatients with late-onset Alzheimer's disease dementia were stratified according to APOE haplotypes, and followed for one year to investigate associations of lipid profile variations and lipophilic statin therapy with changes in co...
متن کاملDiagnosis and management of Parkinson's disease dementia
Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
دوره 49 12 شماره
صفحات -
تاریخ انتشار 2008